Literature DB >> 25759279

Prescribing patterns of anti-migraine medicines in South Africa using a claims database.

Ilse Truter1.   

Abstract

BACKGROUND: Migraine is an expensive condition impacting on the economically active sector of the population. Given the expense of anti-migraine medicine, it is important to monitor the impact of generic prescribing and therapeutic substitution.
OBJECTIVE: The primary aim was to analyse the prescribing patterns and cost of anti-migraine medicines to determine the impact of generic prescribing and prescribing changes over time.
METHOD: A retrospective drug utilisation study was conducted on South African private sector medical insurance claims data for 2011. Results A total of 797 patients received 1583 anti-migraine medicines during 2011. The majority of patients (70.14 %) were females. The average age of patients was 41.61 (SD = 14.91) years. Clonidine was the most frequently prescribed (49.21 % of prescribing frequency; 25.70 % of cost), followed by the triptans [selective serotonin (5-HT1B/1D)-receptor agonists] (27.98 % of prescribing frequency; 45.92 % of cost). Five triptans were prescribed. The average cost per sumatriptan prescription was the lowest (the only triptan with generic equivalents). Rizatriptan was the most frequently prescribed triptan (18.51 % of prescribing frequency; 29.15 % of cost).
CONCLUSION: The results were generally in agreement with previous South African studies. The impact of the introduction of newer triptans and of generic equivalents on prescribing patterns was clear.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25759279     DOI: 10.1007/s11096-015-0089-0

Source DB:  PubMed          Journal:  Int J Clin Pharm


  2 in total

Review 1.  A systematic review of the use of triptans in acute migraine.

Authors:  M J Gawel; I Worthington; A Maggisano
Journal:  Can J Neurol Sci       Date:  2001-02       Impact factor: 2.104

2.  The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis.

Authors:  Elisabeth Hazard; Julie Munakata; Marcelo E Bigal; Marcia F T Rupnow; Richard B Lipton
Journal:  Value Health       Date:  2008-07-30       Impact factor: 5.725

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.